Details
Stereochemistry | ACHIRAL |
Molecular Formula | 3C14H9F3NO2.Al |
Molecular Weight | 867.6474 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Al+3].[O-]C(=O)C1=CC=CC=C1NC2=CC(=CC=C2)C(F)(F)F.[O-]C(=O)C3=CC=CC=C3NC4=CC(=CC=C4)C(F)(F)F.[O-]C(=O)C5=CC=CC=C5NC6=CC(=CC=C6)C(F)(F)F
InChI
InChIKey=OSQHGAXCVAYZPZ-UHFFFAOYSA-K
InChI=1S/3C14H10F3NO2.Al/c3*15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20;/h3*1-8,18H,(H,19,20);/q;;;+3/p-3
Aluminum flufenamate is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. Antiphlogistic pain reliever Opyrin (Aluminum flufenamate) was launched in Japan by Taisho Pharmaceutical in 1967.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D03254 |
|||
Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D03254 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Opyrin Approved UseRheumatoid arthritis, osteoarthritis Launch Date1967 |
|||
Primary | Opyrin Approved UseRheumatoid arthritis, osteoarthritis Launch Date1967 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4590059
Patients with osteoarthritis received aluminium flufenamate in a daily
dose of 750 mg for two weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80167766
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
100000086991
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
16449-54-0
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
17612
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
C79784
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
m5433
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
9NZ7H8YAHG
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
61891-34-7
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
ALTERNATIVE | |||
|
C027885
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
SUB02210MIG
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
240-498-9
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY | |||
|
27881
Created by
admin on Fri Dec 15 16:14:01 GMT 2023 , Edited by admin on Fri Dec 15 16:14:01 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD